Trianni, Inc. Announces License Agreement with Zymeworks Inc. for use of the Trianni Mouse®

San Francisco, CA, Sept. 10, 2019 – Trianni, Inc. (“TRIANNI”) announced today that it has entered into a license agreement with Zymeworks Inc. (“ZYMEWORKS”) for the use of the Trianni Mouse®, a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies, to support ZYMEWORKS’ therapeutic discovery programs.

TRIANNI is pleased that Zymeworks has chosen the Trianni Mouse for the development of novel, fully human, antibody-based therapeutics” said Matthias Wabl, PhD, Chairman, President and CEO of TRIANNI. We are confident that combining Zymeworks’ unique, best-in-class platforms with the power of the Trianni Mouse will lead to the development of transformative medicines for the treatment of underserved patient populations.”

No financial details were disclosed.

Read Full Release